From: Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
Attribute | Characteristics similar to denosumab | Characteristics similar to zoledronic acid | Characteristics similar to clodronate | Characteristics similar to pamidronate |
---|---|---|---|---|
Time until first SRE, months | 27.7 | 19.5 | 15–20 (assume 17.5) | 10.9 |
Time until worsening of pain, months | 5.9 | 5.6 | 3.0 | 0.03–several (assume 3.0) |
Risk of ONJ each year, % | 1.8 | 1.3 | Yes, but value not stated (assume 1.0) | Yes, but value not stated (assume 1.0) |
Risk of renal impairment each year, % | 0 | 9.3 | Yes, but value not stated (assume 5.0) | 8.1 |
Mode of administration | Injection every 4 weeks | 15-min infusion every 4 weeks | Daily oral tablet | 120-min infusion every 4 weeks |
Predicted choice probabilities; country, mean (95% CI) | ||||
France | 90.4 (84.1, 94.2) | 3.9 (2.0, 7.1) | 5.3 (3.1, 9.0) | 0.4 (0.1, 1.0) |
Germany | 93.5 (88.9, 96.3) | 3.6 (1.9, 6.7) | 2.6 (1.5, 4.5) | 0.2 (0.1, 0.6) |
UK | 90.3 (84.8, 94.0) | 3.8 (2.1, 6.6) | 5.6 (3.3, 9.0) | 0.3 (0.1, 0.7) |